| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml |
| Brand | Hyaneb® |
| Indication | Is particularly indicated in patients with cystic fibrosis and in patients with bronchiectasis. Hyaneb® is classified as a medical device and carries a CE mark. |
| Assessment Process | |
| Rapid review commissioned | 10/02/2014 |
| Rapid review completed | 19/03/2014 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation not recommended |